Abbvie Inc.

Abbott Laboratories Corporation

Genentech, Inc.

The Walter and Eliza Hall Institute of Medical Research

The Walter and Eliza Institute of Medical Research

The Walter and Eliza Hall Medical Research Institute

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

Andrew J Souers

Zhi-Fu Tao

Steven Elmore

Xilu Wang

Aaron R Kunzer

Gerard M Sullivan

Michael D Wendt

Le Wang

Xiaohong Song

George A Doherty

Milan Bruncko

Todd M Hansen

Laura A Hexamer

Lisa A Hasvold

Andrew S Judd

Gary T Wang

Hong Ding

Robert A Mantei

Cheol-Min Park

Philip R Kym

Robin R Frey

Andrew M Petros

Thomas Dale Penning

Ju Gao

William J McClellan

Rajesh R Iyengar

Yunsong Tong

Mathew M Mulhern

Chunqiu Lai

David J Madar

Guillaume Laurent Lessene

Peter Colman

Peter Edward Czabotar

Keith G Watson

John A Flygare

Zhili Xin

Chudi Obioma Ndubaku

Jonathan Bayldon Baell

Wayne J Fairbrother

Danette Dudley

Brad E Sleebs

Dariusz Wodka

Chinh Thien Bui

Chang H Park

Brian John Smith

Anthony Mastracchio

George Nikolakopoulos

Keith W Woods

Christine Ann Collins

Carl Steven Rye

Hing L Sham

Gang Liu

Julie M Miyashiro

Tariq Ghayur

Anil Vasudevan

Zhonghua Pei

Bo Liu

Vince S Yeh

Alan S Florjancic

Jianchun Gong

Zhiqin Ji

Nathaniel Catron

Gang Zhao

Andrew C Phillips

Guidong Zhu

Rajeev Goswami

Kamel Izeradjene

Lichun Wang

Stuart J Perper

Michael A Patane

Michael Michaelides

Richard F Clark

Matthew J LaMarche

Gui-Dong Zhu

Martin P Maguire

Lorenzo Benatuil

Michael L Curtin

Yujia Dai

Su-Jen Lai

Courtney A Cullis

Christopher Blackburn

Dennie S Welch

Erwin R Boghaert

Kurt Deshayes

Jane Gong

John K Lynch

Cheng Ji

Xiahong Song

Debra Chao

Jennifer C Freeman

John E Harlan

James A Brown

Archana Thakur

Li Chun Wang

Mary Katherin Verzal

Matthew J Lamarche

Jared C Lewis

Jennifer L Che

Aaron K Kunzer

Juliem Miyashiro

The present invention provides for compounds of Formula (I) wherein A, L, W, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.

1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs.

Anti-EGFR antibody-drug conjugates

The present disclosure provides for compounds of formula (I) wherein A, A, A, A, A, A, A, R, R, R, R, R, R, R, R, R, R, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Macrocyclic MCL-1 inhibitors and methods of use

The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Anti-B7-H3 antibodies and antibody drug conjugates

Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds. One embodiment of such compounds is 4-(4-{[2-(4-chloro-2-fluorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide.

Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases

This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-X.

Methods of treatment using selective Bcl-2 inhibitors

Disclosed are compounds of Formula (IIa), wherein R, R, R, R, R, R, R, and Rare as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors

Disclosed are compound of Formula (Ia), wherein R, R, R, J, Q, X, Y and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (Ia).

Pyridine CDK9 kinase inhibitors

Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.

7-substituted indole Mcl-1 inhibitors

This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-x.

Growing community of inventors

Libertyville, IL, United States of America

Andrew J Souers